Vivos Therapeutics Q3 Earnings Call Highlights

Vivos Therapeutics (NASDAQ:VVOS) reported lower third-quarter revenue and a narrower net loss as it reduced expenses and shifted its business toward sleep centers. The company also warned that its cash balance was insufficient to fund operations for the next 12 months without additional financing.

Revenue fell 5% to approximately $6.4 million for the quarter ended September 30, 2026, from $6.8 million a year earlier, Chief Financial Officer Roman Franklin said. The comparison was the first to include a full quarter of operations from The Sleep Center of Nevada in both periods, following its acquisition in June 2025.

Net loss narrowed to $2 million from $5.4 million, though the latest result included an approximately $2.9 million benefit from reversing a previously recorded Employee Retention Credit liability. Franklin said management concluded that repayment of the credits was no longer deemed probable.

Lower Product Sales Weigh on Margins

Quarterly product revenue declined by approximately $0.4 million to $1.8 million, reflecting lower appliance sales to Vivos Integrated Providers as the company shifted its focus toward sleep centers. Service revenue rose 1% to approximately $4.6 million.

Cost of sales increased 9% to $3.1 million, primarily because of higher diagnostic and patient therapy costs, including additional staff at Vivos treatment centers. Gross margin fell to 52% from 58%, which Franklin attributed to the decline in product revenue.

General and administrative expenses declined 18% to $6.5 million, partly reflecting lower professional fees and the absence of certain prior-year acquisition integration costs. Sales and marketing expenses fell 48% to approximately $0.2 million. Operating loss improved by $0.8 million, or 18%, to $3.9 million.

For the first nine months of 2026, revenue rose 23% to $16.7 million, driven by a 57% increase in service revenue. Net loss widened to $15.2 million from $14.3 million, while cash used in operating activities increased to $12.3 million from $11.5 million.

Cash Shortfall and Nasdaq Compliance

Vivos had approximately $0.2 million in cash and cash equivalents at September 30. Franklin said that, without additional financing, the company’s liquidity position and other factors raise substantial doubt about its ability to continue as a going concern.

The company had approximately $2.3 million in outstanding principal under a senior secured note with Streeterville Capital, due June 10, 2027. Franklin said Vivos had raised equity capital during 2026 and exchanged approximately $6.1 million of Streeterville debt for equity.

Stockholders’ equity was approximately $2.4 million at September 30, below Nasdaq’s $2.5 million minimum. Franklin said Nasdaq notified Vivos in October that it had regained compliance following its SOD Sciences transaction, subject to continued monitoring. Accounting for that transaction remains subject to completion of a purchase price allocation and independent auditor review.

Vivos remains out of compliance with Nasdaq’s $1 minimum bid price requirement, with a compliance period running through December 4. Franklin said the stock had recently traded below $0.10 and described a Nasdaq rule requiring a delisting determination and trading suspension if the closing bid price is $0.10 or less for 10 consecutive business days. Shareholders are scheduled to vote on a proposed reverse stock split at the annual meeting on December 4.

Management Targets Cost Cuts and New Services

Chairman and CEO Kirk Huntsman said Vivos estimates it has eliminated more than $5 million in annual operating costs from late in the third quarter through the date of the call, including workforce reductions and changes to vendor arrangements. Further reductions and efficiencies are under review.

Huntsman said monthly new patient referrals to the company’s two Sleep and Airway Medicine Centers had increased nearly fourfold from May after Vivos worked to better connect diagnosis at its seven Sleep Center of Nevada locations with treatment and continuing care.

The company is also renegotiating payer contracts and developing services that include EEG testing and treatment for non-obstructive sleep apnea disorders, PAP and CPAP setup, and remote monitoring of CPAP users. Huntsman said the payer initiative could produce an annual revenue increase approaching $3.8 million without higher patient volumes or additional services. He cautioned that the broader clinical and payer plans depend on execution, patient participation, payer terms and access to capital.

Outside Nevada, Vivos plans to open a center near a South Palm Cardiovascular Associates location in early 2027. Huntsman said the practice has an estimated population of more than 31,000 patients, but emphasized that they are not already enrolled in Vivos treatment.

Vivos also acquired at least an 11% diluted equity interest in SOD Sciences and a 50% co-ownership interest in its pseudohypoxia early warning test and related intellectual property in October. Huntsman said no cash changed hands and that potential marketing agreements discussed in connection with the transaction were not assured.

Huntsman said the company’s objective is positive operating cash flow in early 2027, supported by sustained cost reductions, improved reimbursement and collections, and development of its clinical programs.

About Vivos Therapeutics (NASDAQ:VVOS)

Vivos Therapeutics is a medical technology company focused on treatments for sleep-disordered breathing, including obstructive sleep apnea. The company works with dental providers to offer non-surgical approaches intended to improve patients’ airways and breathing during sleep. Its Vivos System combines proprietary oral appliances with treatment protocols used by trained dental professionals. The company also provides education and support to providers who offer its therapies. Based in Littleton, Colorado, Vivos primarily serves patients through a network of participating dental practices.